Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
about
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerPhase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.Kinase inhibitors as potential agents in the treatment of multiple myeloma.ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.Antiproliferation activities of NK4 on multiple myeloma
P2860
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@ast
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@en
type
label
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@ast
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@en
prefLabel
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@ast
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@en
P2093
P2860
P1433
P1476
Targeting the pro-survival pro ...... wth of multiple myeloma cells.
@en
P2093
Christine M Stellrecht
Shadia Zaman
Shujun Shentu
Varsha Gandhi
P2860
P304
P356
10.1016/J.NEO.2015.01.006
P577
2015-03-01T00:00:00Z